Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Secondary Prevention of Venous Thrombo Embolism (VTE).

Phase 3

Completed

Conditions: Thromboembolism

Interventions: Drug: Dabigatran
Drug: Warfarin

First Posted Date: 2006-05-24

Last Posted Date: 2014-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2867

Registration Number: NCT00329238

Locations: 🇺🇸
1160.47.01030 Boehringer Ingelheim Investigational Site, Grand Forks, North Dakota, United States
🇨🇦
1160.47.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇲🇽
1160.47.52030 Boehringer Ingelheim Investigational Site, Guadalajara, Jal., Mexico

and more 272 locations

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: BI 1356 dose 1 once daily
Drug: BI 1356 dose 2 once daily
Drug: BI 1356 dose 3 once daily
Drug: Metformin

First Posted Date: 2006-05-19

Last Posted Date: 2014-03-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 302

Registration Number: NCT00328172

Locations: 🇺🇸
1218.5.10026 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
🇨🇦
1218.5.11002 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇺🇸
1218.5.10016 Boehringer Ingelheim Investigational Site, Jacksonville, Florida, United States

and more 68 locations

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-05-17

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 184

Registration Number: NCT00326768

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: pramipexole

First Posted Date: 2006-05-04

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 535

Registration Number: NCT00321854

Locations: 🇺🇸
248.595.0102 Boehringer Ingelheim Investigational Site, Traverse City, Michigan, United States
🇺🇸
248.595.0103 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇮🇹
248.595.39012 Azienda Ospedaliera Pisana- Università degli Studi di Pisa, Pisa, Italy

and more 96 locations

General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-04-27

Last Posted Date: 2023-12-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8000

Registration Number: NCT00319813

Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia

Phase 3

Completed

Conditions: Hypertension
Dyslipidemias

First Posted Date: 2006-04-20

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1695

Registration Number: NCT00316095

Locations: 🇫🇷
ALTI, Angers, France
🇰🇷
Hallym University Sacred Heart Hospital, Kyunggi-do, Korea, Republic of
🇳🇱
Andromed Eindhoven, Eindhoven, Netherlands

and more 20 locations

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

Phase 3

Completed

Conditions: Cerebrovascular Accident

Interventions: Drug: Aggrenox capsule
Other: Acetylsalicylic Acid (ASA)

First Posted Date: 2006-04-06

Last Posted Date: 2014-02-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1295

Registration Number: NCT00311402

Locations: 🇯🇵
9.178.062 Boehringer Ingelheim Investigational Site, Ako, Hyogo, Japan
🇯🇵
9.178.097 Boehringer Ingelheim Investigational Site, Aoi-ku, Shizuoka, Shizuoka, Japan
🇯🇵
9.178.074 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan

and more 148 locations

Case-Control Viramune (Nevirapine) Toxicogenomics Study

Completed

Conditions: HIV Infections

Interventions: Drug: Nevirapine

First Posted Date: 2006-04-05

Last Posted Date: 2013-08-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 889

Registration Number: NCT00310843

Locations: 🇺🇸
1100.1452.01003 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸
1100.1452.99999 Boehringer Ingelheim Investigational Site, Baltimore, Connecticut, United States
🇦🇷
1100.1452.54002 Funcei, Capital Federal, Argentina

and more 99 locations

Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Linagliptin
Drug: Glimepiride

First Posted Date: 2006-04-03

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 333

Registration Number: NCT00309608

Locations: 🇫🇷
1218.6.3305A Euraxi Pharma, Joue les Tours, France
🇸🇰
1218.6.42105 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia
🇸🇰
1218.6.42104 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia

and more 45 locations

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

Phase 4

Completed

Conditions: Parkinson Disease
Depression

Interventions: Drug: Pramipexole
Other: Placebo

First Posted Date: 2006-03-01

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 296

Registration Number: NCT00297778

Locations: 🇦🇹
248.596.43001 Boehringer Ingelheim Investigational Site, Innsbruck, Austria
🇦🇹
248.596.43005 Boehringer Ingelheim Investigational Site, Linz, Austria
🇦🇹
248.596.43003 Boehringer Ingelheim Investigational Site, Graz, Austria

and more 74 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy